Sugi Predict

Sugi Predict / Compounds / SCHEMBL21118924

SCHEMBL21118924

SCHEMBL21118924

CC(C)C(=O)CCCCCNC(=O)C1CCC(CN2C(=O)C=CC2=O)CC1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ NAAA Q02083 1/20 0.38
▸ TTR P02766 1/20 0.37
▸ IL2 P60568 1/20 0.37
▸ LMNA P02545 4/20 0.37
▸ ALDH1A1 P00352 4/20 0.36
▸ HPGD P15428 2/20 0.36
▸ NAMPT P43490 1/20 0.36
▸ GNAI3 P08754 1/20 0.36
▸ GNAO1 P09471 1/20 0.36
▸ GNAI1 P63096 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ CNR1 P21554 1/20 0.35
▸ CNR2 P34972 1/20 0.35
▸ MTNR1A P48039 1/20 0.35
▸ MTNR1B P49286 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24829481 0.89 SMN1; SMN2 (0.41) SMN1; SMN2NAAATTRIL2LMNA
SCHEMBL20936573 0.87 SMN1; SMN2 (0.42) SMN1; SMN2NAAATTRIL2LMNA
SCHEMBL23347014 0.86 SMN1; SMN2 (0.43) SMN1; SMN2NAAATTRIL2LMNA
SCHEMBL6849179 0.86 PTGS1 (0.47) SMN1; SMN2NAAATTRIL2LMNA
SCHEMBL21659263 0.85 NAMPT (0.42) SMN1; SMN2NAAATTRIL2LMNA
SCHEMBL20936656 0.85 SMN1; SMN2 (0.40) SMN1; SMN2NAAATTRIL2LMNA
SCHEMBL15044600 0.85 SMN1; SMN2 (0.40) SMN1; SMN2TTRIL2LMNAALDH1A1
SCHEMBL11990336 0.85 LMNA (0.42) SMN1; SMN2NAAALMNAALDH1A1HPGD
SCHEMBL14872066 0.85 NAAA (0.55) SMN1; SMN2NAAALMNAALDH1A1GNAI3
SCHEMBL2779228 0.85 NAAA (0.55) SMN1; SMN2NAAALMNAALDH1A1GNAI3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230062712-A1 ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF SILVERBACK THERAPEUTICS, INC. 2023-03-02 — — US disclosed
US-11541126-B1 Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof SILVERBACK THERAPEUTICS, INC. (US) 2023-01-03 — — US disclosed
US-20220362396-A1 AMINO-PYRAZINECARBOXAMIDE COMPOUNDS, CONJUGATES, AND USES THEREOF SILVERBACK THERAPEUTICS, INC. 2022-11-17 — — US disclosed
US-20220169660-A1 CYCLIC AMINO-PYRAZINECARBOXAMIDE COMPOUNDS AND USES THEREOF SILVERBACK THERAPEUTICS INC (US) 2022-06-02 — — US disclosed
WO-2022006327-A1 ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF SILVERBACK THERAPEUTICS, INC. (US) 2022-01-06 — — WO disclosed
WO-2021102332-A1 TGFBETAR2 INHIBITOR-LRRC15 ANTIBODY CONJUGATES AND USES THEREOF SILVERBACK THERAPEUTICS, INC. (US) 2021-05-27 — — WO disclosed
US-20210154188-A1 ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF SILVERBACK THERAPEUTICS, INC. 2021-05-27 — — US disclosed
US-20210139477-A1 ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF SILVERBACK THERAPEUTICS, INC. 2021-05-13 — — US disclosed
WO-2021011834-A1 ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF SILVERBACK THERAPEUTICS, INC. (US) 2021-01-21 — — WO disclosed
US-20200199247-A1 ANTIBODY CONJUGATES OF IMMUNE-MODULATORY COMPOUNDS AND USES THEREOF SILVERBACK THERAPEUTICS, INC. 2020-06-25 — — US disclosed
WO-2020056198-A2 SUBSTITUTED BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF SILVERBACK THERAPEUTICS, INC. (US) 2020-03-19 — — WO disclosed
US-20200031798-A1 BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF ARS Pharmaceuticals, Inc. 2020-01-30 — — US disclosed
WO-2019195278-A1 ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF SILVERBACK THERAPEUTICS, INC. (US) 2019-10-10 — — WO disclosed
US-20190169164-A1 BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF SILVERBACK THERAPEUTICS, INC. 2019-06-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210139477-A1 ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF ALK, ALKBH5, ACVR1 SMN1; SMN2 3664/4885NAAA 2452/4885TTR 877/4885
US-20230062712-A1 ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF ASGR1, HAVCR2, FCGR2A SMN1; SMN2 3457/4885NAAA 3852/4885TTR 4337/4885
US-20190169164-A1 BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF TLR8, TLR3, TLR5 SMN1; SMN2 2986/4885NAAA 552/4885TTR 4769/4885
US-20220362396-A1 AMINO-PYRAZINECARBOXAMIDE COMPOUNDS, CONJUGATES, AND USES THEREOF TGFBR2, SMAD2, ACVR2A SMN1; SMN2 3976/4885NAAA 1711/4885TTR 2078/4885
US-20200031798-A1 BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF TLR8, TLR3, TLR5 SMN1; SMN2 2986/4885NAAA 552/4885TTR 4769/4885
US-20200199247-A1 ANTIBODY CONJUGATES OF IMMUNE-MODULATORY COMPOUNDS AND USES THEREOF LTK, TGFBR2, TNIK SMN1; SMN2 4212/4885NAAA 3706/4885TTR 1423/4885
US-20210154188-A1 ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF ALK, ALKBH5, ALKBH3 SMN1; SMN2 3345/4885NAAA 1895/4885TTR 1082/4885
US-11541126-B1 Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof ASGR1, TLR8, HAVCR2 SMN1; SMN2 3597/4885NAAA 2986/4885TTR 4631/4885
US-20220169660-A1 CYCLIC AMINO-PYRAZINECARBOXAMIDE COMPOUNDS AND USES THEREOF TGFBR2, ACVR2A, SMAD2 SMN1; SMN2 3980/4885NAAA 2192/4885TTR 2883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.